Known targets — ChEMBL curated mechanism
PPARDPTGS1PTGS2dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Lysine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSR | P00390 | 2/20 | 0.87 |
| ▸ | ARG2 | P78540 | 4/20 | 0.53 |
| ▸ | ARG1 | P05089 | 3/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.52 |
| ▸ | GRM8 | O00222 | 1/20 | 0.52 |
| ▸ | GRM6 | O15303 | 1/20 | 0.52 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.52 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.52 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.52 |
| ▸ | GRM5 | P41594 | 1/20 | 0.52 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.52 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.52 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.52 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.52 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.52 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.52 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.52 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.52 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.52 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lysine SCHEMBL209698 | 1.00 | GSR (0.87) | GSRARG2ARG1CYP1A2GRM8 | |
| Lysine SCHEMBL1000738 | 1.00 | GSR (0.87) | GSRARG2ARG1CYP1A2GRM8 | |
| Lysine SCHEMBL845918 | 1.00 | GSR (0.87) | GSRARG2ARG1CYP1A2GRM8 | |
| Lysine SCHEMBL209697 | 1.00 | GSR (0.87) | GSRARG2ARG1CYP1A2GRM8 | |
| Lysine SCHEMBL999246 | 1.00 | GSR (0.87) | GSRARG2ARG1CYP1A2GRM8 | |
| Lysine SCHEMBL23295178 | 1.00 | GSR (0.87) | GSRARG2ARG1CYP1A2GRM8 | |
| Lysine SCHEMBL2182542 | 1.00 | GSR (0.87) | GSRARG2ARG1CYP1A2GRM8 | |
| Lysine SCHEMBL4583369 | 1.00 | GSR (0.87) | GSRARG2ARG1CYP1A2GRM8 | |
| Lysine SCHEMBL7082500 | 0.98 | GSR (0.83) | GSRARG2ARG1CYP1A2GRM8 | |
| Lysine SCHEMBL8950821 | 0.94 | GSR (0.77) | GSRARG2ARG1CYP1A2GRM8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1652 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024140670-A1 | CONJUGATE AND USES THEREOF | FULL-LIFE TECHNOLOGIES HK LIMITED (CN) | 2024-07-04 | — | — | WO | claimed |
| WO-2024140917-A1 | ANTI-CD40 ANTIBODY-DRUG CONJUGATE, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | 上海盛迪医药有限公司 | 2024-07-04 | — | — | WO | claimed |
| WO-2024118998-A2 | ENGINEERED ANTI-SARS-COV-2 ANTIBODIES AND METHODS OF USING THE SAME | Vir Biotechnology, Inc. (US) | 2024-06-06 | — | — | WO | claimed |
| EP-4376885-A1 | METHODS FOR TREATING ACUTE MYELOID LEUKEMIA WITH ANTI-ILT3 ANTIBODIES | Merck Sharp & Dohme LLC (US) | 2024-06-05 | — | — | EP | claimed |
| WO-2024112818-A1 | ENGINEERED ANTI-SARS-COV-2 ANTIBODIES AND USES THEREOF | HUMABS BIOMED SA (CH) | 2024-05-30 | — | — | WO | claimed |
| CN-118103359-A | Preparation method of eribulin derivative | 江苏恒瑞医药股份有限公司 | 2024-05-28 | — | — | CN | claimed |
| CN-118020912-A | High-yield spice extraction process | 湖北周黑鸭食品工业园有限公司 | 2024-05-14 | — | — | CN | claimed |
| CN-117510829-A | Nitrogen-branched polyethylene glycol derivative containing amino acid residue | 厦门赛诺邦格生物科技股份有限公司 | 2024-02-06 | — | — | CN | claimed |
| CN-117510828-A | Tri-arm polyethylene glycol derivative containing amino acid residue | 厦门赛诺邦格生物科技股份有限公司 | 2024-02-06 | — | — | CN | claimed |
| WO-2024026019-A1 | METHODS FOR TREATING CHRONIC MYELOMONOCYTIC LEUKEMIA WITH ANTI-ILT3 ANTIBODIES | MERCK SHARP & DOHME LLC (US) | 2024-02-01 | — | — | WO | claimed |
| WO-2004111072-A2 | COMBINATORIAL NUCLEOBASE OLIGOMERS COMPRISING UNIVERSAL BASE ANALOGUES AND METHODS FOR MAKING AND USING SAME | APPLERA CORPORATION (US) | 2004-12-23 | — | — | WO | claimed |
| EP-1370589-A2 | RATIONALLY DESIGNED ANTIBODIES | ALEXION PHARMACEUTICALS, INC. (US) | 2003-12-17 | — | — | EP | claimed |
| US-20030049683-A1 | Immunoglobulin for use in human therapeutics and diagnostics | ALEXION PHARMACEUTICAL, INC. | 2003-03-13 | — | — | US | claimed |
| WO-2002046238-A2 | RATIONALLY DESIGNED ANTIBODIES | ALEXION PHARMACEUTICALS, INC. (US) | 2002-06-13 | — | — | WO | claimed |
| EP-0421682-B1 | Novel peptides, intermediates therefor, process for preparing the same, and antiallergic agents, vasodilators and immunoregulators | HITACHI CHEMICAL CO LTD (JP) | 1997-03-26 | — | — | EP | claimed |
| US-5547983-A | Aromatic and polycyclic compounds and their use in human or veterinary medicine and in cosmetics | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA (CIRD GALDERMA) (FR) | 1996-08-20 | — | — | US | claimed |
| EP-0421682-A1 | Novel peptides, intermediates therefor, process for preparing the same, and antiallergic agents, vasodilators and immunoregulators | HITACHI CHEMICAL CO., LTD. (JP) | 1991-04-10 | — | — | EP | claimed |
| EP-0250559-A1 | PARENTERAL NUTRITION THERAPY WITH AMINO ACIDS | VEECH, Richard L. (US) | 1988-01-07 | — | — | EP | claimed |
| WO-1987003806-A1 | PARENTERAL NUTRITION THERAPY WITH AMINO ACIDS | VEECH RICHARD L | 1987-07-02 | — | — | WO | claimed |
| US-4340592-A | OLICOPEPTIDES FOR DIETARY PURPOSES | ADIBI SIAMAK A | 1982-07-20 | — | — | US | claimed |